Addressing Data Quality Challenges in Lung Cancer Data Within the Observational Medical Outcomes Partnership Common Data Model: Observational Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Overcoming Data Quality Issues in Lung Cancer Research Utilizing the Observational Medical Outcomes Partnership Common Data Model: An Observational Analysis

  • By

  • Jens Declerck

  • Mieke Deschepper

  • Kirsten Colpaert

  • Dipak Kalra

  • Pascal Coorevits

  • June 8, 2026

Share

  • 1

    The study addresses data quality challenges in lung cancer research using the OMOP Common Data Model for effective secondary data use.

  • 2

    Data quality issues can lead to incorrect findings and poor clinical decisions, emphasizing the need for rigorous data management.

  • 3

    The OMOP CDM standardizes health data structures and terminologies, facilitating interoperability and multicenter research.

  • 4

    A data dictionary was created to guide the mapping of lung cancer data to OMOP concepts, serving as a reference for quality evaluation.

  • 5

    The study aims to develop a framework for assessing mapping quality and addressing challenges in implementing the OMOP CDM.

Original Source(s)

Addressing Data Quality Challenges in Lung Cancer Data Within the Observational Medical Outcomes Partnership Common Data Model: Observational Study

  • by Jens Declerck, Mieke Deschepper, Kirsten Colpaert, Dipak Kalra, Pascal Coorevits

  • June 8, 2026

Related Content

Molecular Diagnostics Go Mobile

A smartphone-linked fluorimeter detects infectious disease and cancer biomarkers in 10-minute assays

  • August 31, 2026

  • 3 min
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min